BOSTON–Foundation Medicine has received approval from the U.S. Food and Drug Administration for its FoundationOne Liquid CDx blood test as a companion diagnostic to identify patients with advanced breast cancer who may be eligible for treatment with WILSERDLY (giredestrant) in combination with everolimus.
The Boston-based precision medicine company said FoundationOne Liquid CDx is the first FDA-approved companion diagnostic for the combination therapy, which is intended for patients with estrogen receptor-positive (ER-positive), HER2-negative breast cancer carrying ESR1 mutations.
The approval expands the clinical applications of Foundation Medicine’s liquid biopsy technology, which analyzes tumor-derived genetic material circulating in the bloodstream to identify mutations that may influence treatment decisions.
WILSERDLY, an estrogen receptor antagonist developed by Genentech, is approved for use with everolimus in adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
The treatment is intended for patients whose cancer has returned during or after endocrine-based adjuvant therapy or whose disease has progressed following at least one endocrine-based treatment regimen for metastatic cancer.
FoundationOne Liquid CDx is designed to detect ESR1 mutations and help physicians determine whether patients meet the molecular criteria for the treatment.
The test is covered by Medicare for eligible patients with advanced cancer, according to Foundation Medicine.
ER-positive, HER2-negative breast cancer accounts for approximately 70% of breast cancer cases, making it the most common molecular subtype of the disease.
Although endocrine therapies are widely used to treat these cancers, some tumors develop genetic changes that allow them to resist treatment.
Mutations in the ESR1 gene are among the mechanisms associated with resistance to endocrine therapy and can contribute to disease progression.
According to Foundation Medicine, as many as 40% of patients with ER-positive, HER2-negative breast cancer may develop ESR1 mutations following treatment with cyclin-dependent kinase inhibitors.
Identifying these mutations can help oncologists select treatments that target the specific biological characteristics of a patient’s cancer.
“Breast cancer can mutate and become resistant to early treatments, making biomarker testing at recurrence critical,” said Vera Grossmann, Interim Chief Executive Officer and Chief Operating Officer at Foundation Medicine.
“FoundationOne Liquid CDx has the sensitivity necessary to detect ESR1, helping identify patients who may benefit the most from Genentech’s next-generation SERD combination therapy.”
Companion diagnostics are medical tests used to identify patients who are most likely to benefit from particular treatments or who may face increased risks from certain therapies.
Liquid biopsy tests offer a less invasive alternative to traditional tissue biopsies by detecting cancer-related genetic alterations through blood samples.
These tests can be particularly useful when obtaining tumor tissue is difficult or when physicians need updated information about mutations that emerge during cancer treatment.
Foundation Medicine said the latest approval brings its total number of FDA-approved companion diagnostic indications for breast cancer to nine.
The company said it has more FDA-approved breast cancer companion diagnostic indications than any other comprehensive genomic profiling company.
Across its broader portfolio, Foundation Medicine reports more than 100 approved companion diagnostic indications.
The company’s testing technologies are designed to provide physicians with genomic information that can guide treatment selection across multiple cancer types.
Foundation Medicine also works with pharmaceutical and biotechnology companies to develop companion diagnostics alongside targeted cancer therapies.
The approval was welcomed by Living Beyond Breast Cancer, a nonprofit organization supporting people affected by breast cancer.
“Learning their current treatment for metastatic breast cancer is no longer working causes fear and uncertainty for patients and their loved ones,” said Jean A. Sachs, MSS, MLSP, Chief Executive Officer at Living Beyond Breast Cancer.
“Given the prevalence of metastatic breast cancer patients whose cancer acquires an ESR1 mutation, we are excited to see a new therapy option and a high-quality companion diagnostic approved to help identify patients who may be a good fit for this treatment.”
The FDA approval allows FoundationOne Liquid CDx to be used to identify eligible patients for the WILSERDLY and everolimus combination based on the presence of ESR1 mutations.
The development represents another expansion of precision oncology, where molecular testing helps guide treatment decisions according to the genetic characteristics of individual tumors.


